論文情報

α-Parvin Expression in Breast Cancer Tissues: Correlation with Clinical Parameters and Prognostic Significance

Midori Takeda, Hiroaki Ito, Keisuke Kitahata, Sota Sato, Akira Nishide, Kanae Gamo, Shunsuke Managi, Tohru Tezuka, Akihiko Yoshizawa and Minsoo Kim, Cells 13(18), 1572 (2024).

DOI: doi.org/10.3390/cells13181572

The auxin-inducible degron 2 technology provides sharp degradation control in yeast, mammalian cells, and mice

Aisha Yesbolatova, Yuichiro Saito, Naomi Kitamoto, Hatsune Makino-Itou, Rieko Ajima, Risako Nakano, Hirofumi Nakaoka, Kosuke Fukui, Kanae Gamo, Yusuke Tominari, Haruki Takeuchi, Yumiko Saga, Ken-ichiro Hayashi and Masato T. Kanemaki, Nat Commun. 11, 5701 (2020).

DOI: 10.1038/s41467-020-19532-z

An Efficient Approach Toward Drugging Undruggable Targets

Kanae Gamo, Naomi Kitamoto, Masato T. Kanemaki, and Yusuke Tominari (2020), Hilmar Weinmann and Craig Crews (eds.), Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology, London, The Royal Society of Chemistry, p167-183.

DOI: 10.1039/9781839160691

標的タンパク質分解誘導技術と創薬ベンチャーの動向

Yusuke Tominari and Kanae Gamo, Exp. Med. 38(14), 2020, p2342-2347.

DOI: https://www.yodosha.co.jp/jikkenigaku/book/9784758125352/index.html

蛋白質分解誘導剤の開発

Mitsutoshi Wayama, Kanae Gamo, and Yusuke Tominari, J. Mol. Targeted Ther. Cancer, 18(1), 2020, p56-62.

DOI: https://www.m-review.co.jp/magazine/detail/J0081_1801

ファイメクス社の標的タンパク分解誘導技術

Yusuke Tominari, Farumasia, 56(3), 2020, p248-250.

DOI: 10.14894/faruawpsj.56.3_248

Ligand-induced genetic degradation as a tool for target validation

Aisha Yesbolatova, Yusuke Tominari, and Masato T. Kanemaki. Drug Diecovery Today, Volume 31, April 2019, p91-98.

DOI: 10.1016/j.ddtec.2018.11.001

アーカイブ